If you have been reading about reconstitution and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20 °C or below | Desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity and identity |
| Common synonyms | Thymalfasin, T alpha 1 | Sequence identical to natural fragment |
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
In biochemistry, a kinase (, EC 2.7.-.-) is a protein enzyme that catalyzes the transfer of phosphate groups to substrates. This process is known as phosphorylation. Typically ATP is the phosphate donor. Kinases are pervasive, the human genome codes for about 500 of these enzymes.
Adrenocorticotropic hormone (ACTH; also adrenocorticotropin, corticotropin) is a polypeptide tropic hormone produced by and secreted by the anterior pituitary gland. It is also used as a medication and diagnostic agent. ACTH is an important component of the hypothalamic-pituitary-adrenal axis and is often produced in response to biological stress (along with its precursor corticotropin-releasing hormone from the hypothalamus). Its principal effects are increased production and release of cortisol and androgens by the zona fasciculata and zona reticularis, respectively. ACTH is also related to the circadian rhythm in many organisms. Deficiency of ACTH is an indicator of secondary adrenal insufficiency (suppressed production of ACTH due to an impairment of the pituitary gland or hypothalamus, cf. hypopituitarism) or tertiary adrenal insufficiency (disease of the hypothalamus, with a decrease in the release of corticotropin releasing hormone (CRH)). Conversely, chronically elevated ACTH levels occur in primary adrenal insufficiency (e.g. Addison's disease) when adrenal gland production of cortisol is chronically deficient. In Cushing's disease, a pituitary tumor leads to excessive production of ACTH, which stimulates the adrenal cortex to produce high levels of cortisol.
=== Physical === Lawrencium is the last actinide. Authors considering the subject generally consider it a group 3 element, along with scandium, yttrium, and lutetium, as its filled f-shell is expected to make it resemble the other 7th-period transition metals. In the periodic table, it is to the right of the actinide nobelium, to the left of the 6d transition metal rutherfordium, and under the lanthanide lutetium with which it shares many physical and chemical properties. Lawrencium is expected to be a solid under normal conditions and have a hexagonal close-packed crystal structure (c/a = 1.58), similar to its lighter congener lutetium, though this is not yet known experimentally. The enthalpy of sublimation of lawrencium is estimated at 352 kJ/mol, close to the value of lutetium and strongly suggesting that metallic lawrencium is trivalent with three electrons delocalized, a prediction also supported by a systematic extrapolation of the values of heat of vaporization, bulk modulus, and atomic volume of neighboring elements to lawrencium. This makes it unlike the immediately preceding late actinides which are either known to be (fermium and mendelevium) or expected to be (nobelium) divalent. The estimated enthalpies of vaporization show that lawrencium deviates from the trend of the late actinides and instead matches the trend of the succeeding 6d elements rutherfordium and dubnium, consistent with lawrencium's interpretation as a group 3 element.
Sources: en.wikipedia.org
== Metabolism == Safrole can undergo many forms of metabolism. The two major routes are the oxidation of the allyl side chain and the oxidation of the methylenedioxy group. The oxidation of the allyl side chain is mediated by a cytochrome P450 complex, which will transform safrole into 1′-hydroxysafrole. The newly formed 1′-hydroxysafrole will undergo a phase II drug metabolism reaction with a sulfotransferase enzyme to create 1′-sulfoxysafrole, which can cause DNA adducts. A different oxidation pathway of the allyl side chain can form safrole epoxide. So far, this has only been found in rats and guinea pigs. The formed epoxide is a small metabolite due to the slow formation and further metabolism of the compound. An epoxide hydratase enzyme will act on the epoxide to form dihydrodiol, which can be secreted in urine. The metabolism of safrole through the oxidation of the methylenedioxy proceeds via the cleavage of the methylenedioxy group. This results in two major metabolites: allylcatechol and its isomer, propenylcatechol. Eugenol is a minor metabolite of safrole in humans, mice, and rats. The intact allyl side chain of allylcatechol may then be oxidized to yield 2′,3′-epoxypropylcatechol. This can serve as a substrate for an epoxide hydratase enzyme, and will hydrate the 2′,3′-epoxypropylcatechol to 2′,3′-dihydroxypropylcatechol. This new compound can be oxidized to form propionic acid (PPA), which is a substance that is related to an increase in oxidative stress and glutathione S-transferase activity.
== Further reading == Pohlschroder, Mechthild; Pfeiffer, Friedhelm; Schulze, Stefan; Halim, Mohd Farid Abdul (1 September 2018). "Archaeal cell surface biogenesis". FEMS Microbiology Reviews. 42 (5): 694–717. doi:10.1093/femsre/fuy027. PMC 6098224. PMID 29912330.
=== Procedure === Typically, PCR consists of a series of 20–40 repeated temperature changes, called thermal cycles, with each cycle commonly consisting of two or three discrete temperature steps (see figure below). The cycling is often preceded by a single temperature step at a very high temperature (>90 °C (194 °F)), and followed by one hold at the end for final product extension or brief storage. The temperatures used and the length of time they are applied in each cycle depend on a variety of parameters, including the enzyme used for DNA synthesis, the concentration of bivalent ions and dNTPs in the reaction, and the melting temperature (Tm) of the primers. The individual steps common to most PCR methods are: initialization, annealing and extension.
The Supreme Soviet (successor of the Congress of Soviets) was nominally the highest organ of state authority for most of the Soviet history, at first acting as a rubber stamp institution, approving and implementing all decisions made by the party. However, its powers and functions were extended in the late 1950s, 1960s, and 1970s, including the creation of new state commissions and committees. It gained additional powers relating to the approval of the Five-Year Plans and the government budget. The Supreme Soviet elected a Presidium (successor of the Central Executive Committee) to wield its power between plenary sessions, ordinarily held twice a year, and appointed the Supreme Court, the Procurator General and the Council of Ministers (known before 1946 as the Council of People's Commissars), headed by the Chairman (Premier) and managing an enormous bureaucracy responsible for the administration of the economy and society. State and party structures of the constituent republics largely emulated the structure of the central institutions, although the Russian SFSR, unlike the other constituent republics, for most of its history had no republican branch of the CPSU, being ruled directly by the union-wide party until 1990. Local authorities were organized likewise into party committees, local Soviets and executive committees. While the state was a de jure federation with a nominally federal constitution, the party was de facto centralized and unitary. The state security police (the KGB and its predecessor agencies) played an important role in Soviet politics.
Sources: en.wikipedia.org
Peptide nucleic acids (PNAs) are synthetic oligonucleotides in which the sugar-phosphate backbone of the DNA or RNA is replaced by a neutral N-(2-aminoethyl)-glycine peptide-like backbone. This allows PNAs to hybridize with complementary DNA or RNA with high affinity and specificity, maintaining their ability to be amplified via polymerase chain reaction (PCR). Unlike DNA/RNA, PNAs are able to resist degradation by nucleases and proteases. In a PNA-encoded library system, unique PNA sequences serve as molecular tags that are covalently attached to small molecules that are produced using combinatorial methods that generate large collections of related compounds. These PNA tags act as barcodes that encode the identity of the PNA allowing for downstream identification. PNA libraries are synthesized using solid-phase peptide synthesis (SPPS), allowing library assembly on resin similar to other peptide libraries. This contrasts with DNA-encoded libraries, which often require enzymatic ligation steps and can be limited by the chemical properties of DNA. The neutrality and stability of the PNA backbone means that PNA tags can tolerate conditions that might degrade DNA tags, and the strong hybridization to complementary nucleic acids which allows PNA tags to be decoded wither by direct hybridization or by conversion into DNA, which can then be amplified and analyzed ,<ref. PNA-encoded libraries have been used in several different formats, including microarray hybridization, selection against biological targets, and PCR-based decoding following selection.
=== Pregnancy === Oxazepam, when taken during the third trimester, causes a definite risk to the neonate, including a severe benzodiazepine withdrawal syndrome including hypotonia, reluctance to suck, apnoeic spells, cyanosis, and impaired metabolic responses to cold stress. Floppy infant syndrome and sedation in the newborn may also occur. Symptoms of floppy infant syndrome and the neonatal benzodiazepine withdrawal syndrome have been reported to persist from hours to months after birth.
After exploring running in several previous cycles, in January 2007, Biden declared his candidacy in the 2008 elections. Biden focused on the Iraq War, his record as chairman of major Senate committees, and his foreign-policy experience. Biden was noted for his one-liners during the campaign; in one debate he said of Republican candidate Rudy Giuliani, "There's only three things he mentions in a sentence: a noun, and a verb and 9/11." Biden had difficulty raising funds, struggled to draw people to his rallies, and failed to gain traction against the high-profile candidacies of Barack Obama and Hillary Clinton. He never rose above single digits in national polls of the Democratic candidates. In the first contest on January 3, 2008, Biden placed fifth in the Iowa caucuses, garnering slightly less than one percent of the state delegates. He withdrew from the race that evening. Despite its lack of success, Biden's 2008 campaign raised his stature in the political world. In particular, it changed the relationship between Biden and Obama. Although they had served together on the Senate Foreign Relations Committee, they had not been close: Biden resented Obama's quick rise to political stardom, while Obama viewed Biden as garrulous and patronizing. Having gotten to know each other during 2007, Obama appreciated Biden's campaign style and appeal to working-class voters, and Biden said he became convinced Obama was "the real deal".
Sources: en.wikipedia.org
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.
Mass spectrometry gives the molecular mass, which is compared with the calculated value. Reversed-phase liquid chromatography shows purity and the presence of related impurities. Peptide mapping can verify the amino acid sequence when a higher level of detail is needed.
It reports the tests the supplier performed, which may vary between laboratories and lots. Methods and acceptance criteria are not standardised across suppliers. Buyers often request the actual chromatograms and spectra rather than a summary statement.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.